Orphan drug pricing may warrant a competition law investigation

BMJ (Online)

Volumn 341, Issue 7782, 2010, Pages 1084-1086

  Roos, Jonathan C P ^a   Hyry, Hanna I ^a   Cox, Timothy M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; ECULIZUMAB; IDURONATE 2 SULFATASE; IMIGLUCERASE; ORPHAN DRUG; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; SAPROPTERIN;

DRUG COST; DRUG INDUSTRY; DRUG MARKETING; EUROPEAN UNION; HEALTH CARE FINANCING; HEALTH CARE POLICY; LAW; PRIORITY JOURNAL; SHORT SURVEY;

DRUG COSTS; ECONOMIC COMPETITION; EUROPEAN UNION; ORPHAN DRUG PRODUCTION;

EID: 78449275391     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c6471     Document Type: Short Survey

References (0)